Fetal Down syndrome screening models for developing countries; Part I: Performance of Maternal Serum Screening
نویسندگان
چکیده
منابع مشابه
Brief Communication: Maternal Plasma Autoantibodies Screening in Fetal Down Syndrome
Imbalance in the metabolites levels which can potentially be related to certain fetal chromosomal abnormalities can stimulate mother's immune response to produce autoantibodies directed against proteins. The aim of the study was to determine the concentration of 9000 autoantibodies in maternal plasma to detect fetal Down syndrome. Method. We performed 190 amniocenteses and found 10 patients wit...
متن کاملMaternal serum screening for fetal genetic disorders.
Maternal serum analyte screening is an integral component of contemporary antenatal care. Based on elevated MSAFP levels, 85% to 90% of NTDs (e.g., anencephaly or spina bifida) can be detected. Using a combination of serum analytes (e.g., MSAFP, hCG, UE3) 55% to 60% of fetal Down's syndrome can be detected. Future strategies for Down's syndrome screening may include the use of new markers such ...
متن کاملHow important is consent in maternal serum screening for Down syndrome in France? Information and consent evaluation in maternal serum screening for Down syndrome: a French study.
OBJECTIVES To evaluate the level of information and informed consent for maternal serum screening (MSS) for Down syndrome (DS) in the second trimester of pregnancy and analyse the exercise of autonomy towards the test by the women concerned. METHODS We studied the population of pregnant women attending obstetric consultations in two French hospitals over a 3-month period. The women were assig...
متن کاملScreening for Down syndrome
In 1866 J Langdon Down made the observation of a subgroup of patients with particular facial features and mental handicap in the outpatient department of the London Hospital 1. In the late 1950’s, it was shown that an extra acrocentric chromosome was present in persons with Down syndrome, resulting in a diploid chromosome number of 47. It is now known that Down syndrome results when either the ...
متن کاملSecond-trimester maternal serum invasive trophoblast antigen: a marker for Down syndrome screening.
Immunosuppressive Drug Monitoring. Ther Drug Monit 2002;24:59–67. 12. Novartis. Neoral C-2 monitoring: scientific evidence and clinical validation. http://www.transplantation-schweiz.ch/e/sandimmun/Scientific_Monograph. pdf (accessed June 2004). 13. Morris RG, Russ GR, Cervelli MJ, Juneja R, McDonal SP, Mathew TH. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMC Health Services Research
سال: 2019
ISSN: 1472-6963
DOI: 10.1186/s12913-019-4446-x